INTRODUCTION

Biliary self-expanding metal stents (SEMSs) were first introduced in the late 1980s in the United States. SEMSs were initially marketed as uncovered mesh stents, which maintained longer patency than fixed-size plastic stents. Historically, uncovered metal stents (UCMSs) have been solely used for palliation to relieve biliary obstruction secondary to unresectable malignant pancreatic and biliary tract tumors. Because the stent is uncovered, significant tissue ingrowth occurs with time, which prevents stent migration; however, when the stent needs to be removed for obstruction or any other reason, it becomes a major barrier to a safe endoscopic extraction. Currently, three main subtypes of SEMSs are available: UCMSs, partially covered metal stents (PCMSs), and fully covered metal stents (FCMSs). As the stent becomes more covered, the risk of spontaneous migration increases; however, at the same time, it also becomes more amenable to endoscopic extraction, thus expanding its use for benign indications such as refractory biliary strictures and post-liver transplant anastomotic strictures. UCMSs should be considered for palliation of malignant strictures only, and their placement for benign biliary strictures is strongly discouraged.

Self-expanding metal stents play a crucial role in the management of patients with biliary obstruction. Endoscopic extraction of uncovered metal stents (UCMSs) and partially covered metal stents (PCMSs) could be challenging because of tissue ingrowth. No standardized technique can guarantee universal success. We present our technique and experience of endoscopic extraction of biliary stents in two patients with a UCMS and three patients with a PCMS. Three of the five patients had a previous failed attempt of stent extraction at an outside hospital. Overall, our composite success rate was 80% (4/5). The individual success rate was 100% (3/3) for PCMSs and 50% (1/2) for UCMSs. The stent-in-stent technique, in which a fully covered metal stent is placed through an existing UCMS/PCMS, was used in 60% (3/5) of the cases, with a success rate of 66.7% (2/3). We share our algorithmic approach to each case, with detailed emphasis on the technical aspects of the procedure. Clin Endosc 2020 Sep 8. [Epub ahead of print]

Key Words: Biliary partially covered metal stent; Biliary uncovered metal stent; Endoscopic removal
Consequently, considerable emphasis has been placed on selecting the appropriate subtype of SEMSs depending on the indication. Although rare, scenarios still arise in current practice when removal of a UCMS or PCMS is desired. Novel methods such as the covered-stent-in-uncovered-stent technique, initially described for esophageal stent removal, have been successfully extrapolated to biliary SEMSs; however, the experience remains limited. In this article, we describe our experience (along with videos), with emphasis on the technique for endoscopic extraction, of difficult to remove PCMSs and UCMSs from the extrahepatic biliary tree.

CASE REPORTS

Over a span of 12 months (2019–2020), five cases of endoscopic extraction of biliary PCMSs (3/5) and UCMSs (2/5) were encountered.

Demographics
The cohort included four women and one man. The average age was 75.4 years (range, 61–82 years).

Etiology
All patients had initially presented with symptoms and signs of biliary obstruction, which had prompted the placement of a PCMS or a UCMS. A UCMS had been placed for palliation in two patients, one with a confirmed malignancy (ampulla adenocarcinoma) and the other with a presumed malignant etiology (gallbladder cancer, later found to be benign on post-cholecystectomy pathology). A PCMS was placed in three patients with main-duct intraductal papillary mucinous neoplasm, anomalous pancreaticobiliary junction with choledochocele, and choledocholithiasis.

Clinical presentation
Three patients had presented with cholangitis and the other two patients were planned for elective stent removal.

First procedure
Of the five patients, three initially presented at an outside hospital and underwent a first attempt of endoscopic extraction at the respective hospitals; however, stent extraction failed in all three cases. All three patients were consequently transferred to our center. One of the three patients underwent placement of an FCMS through the existing UCMS and a percutaneous transhepatic drain in the setting of cholangitis before transfer. The remaining two of the five patients presented to our center for an index procedure, and both of them underwent placement of an FCMS via an existing UCMS/PCMS and were scheduled for repeat endoscopic retrograde cholangiopancreatography (ERCP) in 6 weeks for an attempt at stent extraction.

Second procedure
Two patients with an FCMS within a UCMS (as placed in the prior procedure) underwent a stent extraction attempt using rat-toothed and alligator forceps, with success in one and failure in other. Of the three patients with a PCMS, one had an FCMS placed through the existing PCMS in the prior procedure. Successful removal of stents was achieved in all three patients with the use of rat-toothed and alligator forceps. In addition, one of the patients (PCMS alone) required balloon dilation of the distal part of the stent to aid the extraction.

The details of each case with specific interventions and outcomes are summarized in Table 1.

Technique
Our approach is described below in a stepwise manner (Fig. 1):

The first step remains sweeping the lumen of the PCMS or UCMS in its entire length across the extrahepatic biliary tree using a balloon catheter with appropriate size. Beyond debris removal, it improves visualization for the assessment of the extent and severity of tissue ingrowth and allows the stent mesh (of the uncovered segment) to more easily expand and collapse when traction is applied at the time of stent removal.

If the tissue ingrowth is limited in extent (PCMS) and severity, a direct attempt at stent removal using rat-toothed or alligator forceps is a reasonable first step (Supplementary Video 1).

If the tissue ingrowth is extensive and/or across the entire length of the stent (UCMS), the stent-in-stent technique should be considered. Ideally, a FCMS 2 cm longer and having the same or larger diameter than the existing stent (as safely possible) should be selected. The deployment of this stent should be accurate in terms of its position, allowing it to bridge the entire existing UCMS/PCMS and avoiding bifurcation. Repeat ERCP should thereafter be scheduled in 4–6 weeks.

To grab the stent, any of the following accessories can be used: rat-toothed, alligator, or raptor grasper. It is important to grab at least three strands of the stent mesh (one diamond) to allow an adequate grasp and the application of force (Supplementary Video 2). Moreover, if there is a preexisting FCMS within a UCMS/PCMS, then it is important to grasp both stents together, applying the same principles.

Once the stent/s has/have been adequately grasped, the grasping forceps should be tightly pulled followed by slow
### Table 1. Descriptive Summary of the Demographics, Etiology, Clinical Presentation, Interventions, and Outcomes for Each Case

<table>
<thead>
<tr>
<th>Age</th>
<th>Gender</th>
<th>Etiology</th>
<th>Type of stent</th>
<th>Presentation</th>
<th>First attempt at stent removal</th>
<th>Outcome</th>
<th>Intervention</th>
<th>Second attempt at stent removal</th>
<th>Accessories</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>82</td>
<td>F</td>
<td>Biliary obstruction- 1. Ampullary adenocarcinoma</td>
<td>UCMS</td>
<td>Cholangitis</td>
<td>Yes (outside hospital)</td>
<td>Failure</td>
<td>1. FCMS placed through pre-existing UCMS 2. PTC drain placement 3. Antibiotics 4. Referral to tertiary center</td>
<td>Yes</td>
<td>1. Rat toothed forceps 2. Alligator forceps</td>
<td>Success (both stents removed)</td>
</tr>
<tr>
<td>95</td>
<td>F</td>
<td>Biliary obstruction- 1. Main duct IPMN</td>
<td>PCMS</td>
<td>Cholangitis</td>
<td>Yes (outside hospital)</td>
<td>Failure</td>
<td>1. Antibiotics 2. Referral to tertiary center</td>
<td>Yes</td>
<td>1. Raptor grasper 2. Rat toothed forceps</td>
<td>Success</td>
</tr>
<tr>
<td>69</td>
<td>F</td>
<td>Biliary obstruction- 1. Gallbladder cancer (post cholecystectomy, pathology negative for cancer)</td>
<td>UCMS</td>
<td>Scheduled stent removal</td>
<td>No</td>
<td>N/A</td>
<td>1. FCMS placed through pre-existing UCMS 2. Schedule repeat ERCP in 6 wks</td>
<td>Yes</td>
<td>1. Raptor grasper 2. Rat toothed forceps 3. Alligator forceps 4. Snare</td>
<td>Failure (only FCMS could be removed; referred for surgical intervention)</td>
</tr>
</tbody>
</table>

ERCP, endoscopic retrograde cholangiopancreatography; FCMS, fully covered metal stent; IPMN, intraductal papillary mucinous neoplasm; N/A, not applicable; PCMS, partially covered metal stent; PTC, percutaneous transhepatic cholangiogram; UCMS, uncovered metal stent.
**Step: 1**
Cannulation through the stent followed by balloon sweep

**Step: 2**
Assess for proximal migration

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balloon dilation of distal bile duct up to the size of stent</td>
<td></td>
</tr>
</tbody>
</table>

**Step: 3**
Characterize stent: type, length, diameter, extent of tissue ingrowth

<table>
<thead>
<tr>
<th>1. PCMS</th>
<th>1. UCMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Short in length</td>
<td>2. Long in length</td>
</tr>
<tr>
<td>3. Minimal tissue ingrowth</td>
<td>3. Significant tissue ingrowth</td>
</tr>
</tbody>
</table>

Direct attempt at stent removal using rat tooth/alligator/raptor forceps +/- balloon dilation within stent

Failure

Consider stent in stent technique and plan repeat ERCP in 4-6 weeks to attempt removing both stents using rat tooth/alligator/raptor forceps

---

**DISCUSSION**

In current practice, SEMSs play a crucial role in the management of biliary obstruction, especially for palliation in cancer patients who are not surgical candidates and for benign refractory strictures. Depending on the extent of covering, three subtypes of SEMSs are commercially available: FCMS, PCMS, and UCMS. The more uncovered the stent is, the greater is the amount of tissue ingrowth that develops over time, which leads to less risk of migration but greater difficulty of stent removal, if later attempted. Infrequently, patients with a UCMS or PCMS who have either outlived their life expectancy or were lost to follow-up or were initially intervened on the basis of an incorrect presumptive diagnosis return for stent extraction. The endoscopic extraction of UCMSs and PCMSs could be very challenging, and no standard technique can guarantee universal success.

This is one of those areas in endoscopy in which every individual case is best dealt with a specific tailored plan. We here share our experience of two cases with a UCMS and three cases with a PCMS. Three of the five cases had a failed attempt of stent extraction at an outside hospital. Overall, our composite success rate was 80% (4/5). The individual success rate was 100% (3/3) for PCMSs and 50% (1/2) for UCMSs. The stent-in-stent technique in which an FCMS is placed through the existing UCMS/PCMS was used in 60% (3/5) of the cases, with a success rate of 66.7% (2/3). One failed removal oc-
curred in a patient with a UCMS. The major reason for failure to extract was the long size of the UCMS, which extended into the left main hepatic duct. We were unable to bridge the proximal part of the UCMS with a fully covered stent owing to the risk of blocking the right main hepatic duct. This patient was eventually referred for surgery.

In conclusion, one approach may not fit all cases of UCMS and PCMS extraction from the biliary tree. For a successful and safe outcome, we strongly recommend a stepwise approach. It starts with sweeping of the existing stent to remove any biliary sludge and debris, followed by characterizing the existing stent (type, length, and extent and severity of tissue ingrowth) and subsequently choosing the appropriate strategy (as detailed above). Careful application of each technical step of the chosen approach may make the difference between a successful and failed outcome.

Conflicts of Interest

Muhammad K. Hasan is a consultant for Boston Scientific and Olympus America. The other authors have no financial conflicts of interest.

Author Contributions

Conceptualization: Deepanshu Jain
Data curation: DJ, Assaf Stein, Muhammad K. Hasan
Formal analysis: DJ
Methodology: DJ
Supervision: MKH
Writing-original draft: DJ, AS
Writing-review&editing: MKH

ORCID

Assaf Stein: https://orcid.org/0000-0002-8532-0788

REFERENCES